However, although representing the minority, FCR may still be justifiably offered as an alternative to novel therapies for young, fit patients with mIGHV CLL and absence of TP53 aberrancy with the aim of achieving long-term disease control. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.